@article{463c2fe385024b82a55b8bd1f1d8f685,
title = "Endpoints and Outcomes After Immunotherapy for Food Allergy: What Is Meaningful for Patients?",
abstract = "Multiple novel interventions for food allergy are currently at various stages of development with the goal of reducing or eliminating allergic reactions. However, the relative success of these therapeutics in achieving meaningful, long-term improvements to patients{\textquoteright} lives is difficult to determine as there is currently very limited understanding of the degree of alignment between clinical trial efficacy endpoints and patient-centered outcomes. Furthermore, outcome measures used in clinical trials of food allergy immunotherapies vary widely, are often misinterpreted, and not necessarily consistent with what patients expect to achieve through treatment. This review aims to assist clinicians in critically interpreting outcomes reported in clinical trials and accurately communicating risks and outcomes to patients when practicing shared decision-making.",
keywords = "Food allergy, Immunotherapy, Outcome measurement, Patient-centered",
author = "Melanie Lloyd and Nandinee Patel and Daniel Munblit and Tang, {Mimi L.K.}",
note = "Funding Information: Conflicts of interest: D. Munblit is a chair of the Core Outcome Measures for Food Allergy (COMFA) consortium funded by European Cooperation in Science and Technology (COST). M. L. K. Tang declares funding from the following organizations: National Health and Medical Research Council (Australia), Prota Therapeutics, Allergy and Immunology Foundation of Australasia, and Murdoch Children{\textquoteright}s Research Institute; has provided consultancy services to Pfizer , Novartis , and Prota Therapeutics; and holds stock/options in Prota Therapeutics. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflicts of interest: D. Munblit is a chair of the Core Outcome Measures for Food Allergy (COMFA) consortium funded by European Cooperation in Science and Technology (COST). M. L. K. Tang declares funding from the following organizations: National Health and Medical Research Council (Australia), Prota Therapeutics, Allergy and Immunology Foundation of Australasia, and Murdoch Children's Research Institute; has provided consultancy services to Pfizer, Novartis, and Prota Therapeutics; and holds stock/options in Prota Therapeutics. The rest of the authors declare that they have no relevant conflicts of interest. No funding was received for this work. Publisher Copyright: {\textcopyright} 2023",
year = "2023",
month = apr,
doi = "10.1016/j.jaip.2023.01.033",
language = "English",
volume = "11",
pages = "998--1007",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier BV",
number = "4",
}